Vibalogics Bolsters Scientific Advisory Board with Two New Appointments

Vibalogics, a global contract development and manufacturing organization (CDMO) and leader in the virotherapy services market has announced two new appointments to its Scientific Advisory Board. Dr. Paula Alves, Ph.D. and Dr. Johannes van der Loo, Ph.D. are the latest experts to join the board and will contribute a wealth of knowledge and deep industry expertise across biotherapeutic research and bioprocessing applications.

The Scientific Advisory Board was established in 2021 to support Vibalogics through the ongoing development of its fully-integrated service offering for customers progressing early clinical through late-phase oncolytic virus, viral vaccine, and gene therapy products, and overall business investment and expansion plans underway at its Cuxhaven, Germany and Boxborough, Massachusetts facilities.

Dr. Paula Alves, Ph.D. is CEO of iBET (The Instituto de Biology Experimental e Tecnológica) and Professor at NOVA University of Lisbon. With experience in the production of biopharmaceuticals such as viral vectors and vaccines. Dr. Alves has also worked extensively on the development of 3D-culture systems for expansion and differentiation of stem cells in bioreactors for cell therapy and regenerative medicine applications.

Dr. Johannes van der Loo, Ph.D. is Director of the Clinical Vector Core at the Children’s Hospital of Philadelphia, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, and Adjunct Associate Professor of Pathology and Laboratory Medicine at the University of Pennsylvania. In his current role, he is responsible for manufacturing of adeno-associated virus (AAV) and lentiviral vectors for pre-clinical pharmacology and toxicology studies and for clinical use.

Vibalogics’ Scientific Advisory Board is led by Dr. Kai Lipinski, Chief Scientific Officer at Vibalogics. Dr. Alves and Dr. van der Loo join founding board members Dr. Guangping Gao, Ph.D., Dr. Alain Pralong, Ph.D., and Dr. Stephen Russell, M.D., Ph.D.

Commenting on the recent announcement, Dr. Lipinski shares: “We are very pleased to welcome our newest board members Dr. Alves and Dr. van der Loo. Together, with our existing board members, Vibalogics looks to remain a premier partner to companies working to bring viral-derived products to clinic and the commercial market. The Scientific Advisory Board has been instrumental in helping shape considerations on the future direction of our CDMO services business, by maintaining a strong pulse on the clinical progress across the therapeutic and vaccine modalities we support, reviewing key industry trends, and evaluating new and emerging process and analytical technologies to optimize our offering ahead for our clients.”

About Vibalogics

Since 2003, Vibalogics has operated as a specialized global Contract Development and Manufacturing Organization (CDMO) offering process and analytical development, manufacturing, testing, and fill-finish services to innovators developing transformational virotherapy products. In April 2022, the organization was acquired by Recipharm, a top global CDMO. With operations in Boxborough and Watertown, MA, USA, and Cuxhaven, Germany, Vibalogics supports its customers in the development and commercialization of oncolytic viruses, gene therapies and viral vaccines. www.vibalogics.com

For further information, images and interview opportunities, please contact Lara Lovenbury at ramarketing: lara@ramarketingpr.com | +44 (0)7972471903 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm and our services, please visit www.recipharm.com